{
  "emaEpar": [
    {
      "activeSubstance": "Treosulfan",
      "conditionIndication": "Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases., ",
      "inn": "treosulfan",
      "marketingAuthorisationDate": "2019-06-20 00:00:00",
      "marketingAuthorisationHolder": "medac Gesellschaft f\u00fcr klinische Spezialpr\u00e4parate mbH",
      "medicineName": "Trecondi",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trecondi"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Treosulfan",
  "nciThesaurus": {
    "casRegistry": "299-75-2",
    "chebiId": "",
    "chemicalFormula": "C6H14O8S2",
    "definition": "The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.",
    "fdaUniiCode": "CO61ER3EPI",
    "identifier": "C1257",
    "preferredName": "Treosulfan",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C222"
    ],
    "synonyms": [
      "(S-(R*,R*))-1,2,3,4-butanetetrol,1,4-dimethanesulfonate",
      "1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-",
      "Dihydroxybusulfan",
      "L-Threitol 1,4-dimethanesulfonate",
      "Ovastat",
      "TREOSULFAN",
      "Trecondi",
      "Treosulfan",
      "Treosulphan",
      "Tresulfon",
      "treosulfan"
    ]
  }
}